Authors: Charafe-Jauffret, E Eisinger, F Mathoulin-Portier, MP Hassoun, J Birnbaum, D Sobol, H Jacquemier, J

Citation: E. Charafe-jauffret et al., PS2-expression in BRCA1-associated breast cancers, ANTICANC R, 21(4B), 2001, pp. 2877-2881

Authors: Charafe-Jauffret, E Jacquemier, J Lelong, B Meynard, P Mathoulin-Portier, MP Houvenhaegel, G Hassoun, J

Citation: E. Charafe-jauffret et al., Mammary carcinoma arising in microglandular adenosis: a case report, ANN PATHOL, 21(5), 2001, pp. 435-438

Authors: Mathoulin-Portier, MP Viens, P Cowen, D Bertucci, F Houvenaeghel, G Geneix, J Puig, B Bardou, VJ Jacquemier, J

Citation: Mp. Mathoulin-portier et al., Prognostic value of simultaneous expression of p21 and mdm2 in breast carcinomas treated by adjuvant chemotherapy with antracyclin, ONCOL REP, 7(3), 2000, pp. 675-680

Authors: Jacquemier, J Mathoulin-Portier, MP Valtola, R Charafe-Jauffret, E Geneix, J Houvenaeghel, G Puig, B Bardou, VJ Hassoun, J Viens, P Birnbaum, D

Citation: J. Jacquemier et al., Prognosis of breast-carcinoma lymphagenesis evaluated by immunohistochemical investigation of vascular-endothelial-growth-factor receptor 3, INT J CANC, 89(1), 2000, pp. 69-73

Authors: Mathoulin-Portier, MP Meynard, P Charton-Bain, MC Escoute, M Bardou, VJ Puig, B Viens, P Cowen, D Houvenaeghel, G Hassoun, J Jacquemier, J

Citation: Mp. Mathoulin-portier et al., Peritumoral vascular invasion in women with node-negative breast cancer, receiving no adjuvant therapy, ANTICANC R, 19(1B), 1999, pp. 843-847